Robert Egge

Executive Director, AIM

Chief Public Policy Officer, Alzheimer's Association

Robert Egge is the chief public policy officer of the Alzheimer's Association and the executive director of the Alzheimer's Impact Movement (AIM), a separately incorporated advocacy affiliate of the Association. In these roles, Egge oversees government affairs, policy development and grassroots advocacy teams working to secure policies to improve the lives of all those affected by dementia.

In his tenure, Egge has led the Association in achieving several major federal milestones, including the passage of the National Alzheimer's Project Act (NAPA) which mandated the creation of the first national plan to fight Alzheimer's, and the Alzheimer's Accountability Act (AAA) which requires the annual completion of a professional judgment budget by the National Institutes of Health for Alzheimer's research. Following a $289 million increase signed into law in March 2022, and added to current NIH spending, annual federal funding for Alzheimer's research will be more than $3.4 billion.

Egge oversaw efforts to incorporate the Younger Onset Alzheimer's Act within the Supporting Older Americans Act in 2020 - ensuring that these individuals will have access to vital and affordable services regardless of age. He managed the Association's work to pass the bipartisan BOLD Infrastructure for Alzheimer's Act, legislation that is critical to addressing Alzheimer's as a public health issue. In addition, Egge drove the Association's support for a 2016 decision by the Centers for Medicare & Medicaid Services to ensure people living with dementia have access to care planning with a medical professional through Medicare for the first time in history. Egge has led efforts to increase the number of state Alzheimer's plans to more effectively address the disease at local levels. As a result, 49 states plus the District of Columbia and Puerto Rico currently have published plans. In 2019 alone, under his leadership the Association secured more than $100 million in state funding for dementia-specific care and support services,research, and public health activities.

From 2017-2021, Egge served on the U.S. Department of Health and Human Services' (HHS) Advisory Council on Alzheimer's Research, Care, and Services. This advisory council, created by the National Alzheimer's Project Act, provides guidance to both the HHS Secretary and Congress on matters of Alzheimer's policy.

Prior to joining the Association, Egge served as executive director of the Alzheimer's Study Group, a blue-ribbon task force co-chaired by former House Speaker Newt Gingrich and former Nebraska Senator Bob Kerrey. He led the group in a review of the challenges posed by the mounting Alzheimer's crisis, and managed the development of the group's national assessment,strategy and specific policy proposals.

Egge's articles and editorials have appeared in a variety of publications including The New York Times, the Financial Times and Health Affairs. He is often invited to testify before Congress on Alzheimer's issues, and frequently speaks on Alzheimer's policy through television, radio and print interviews.

The Alzheimer's Association is the leading voluntary health organization in Alzheimer's care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia - by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia. Formore information, visit

The Alzheimer's Impact Movement (AIM) is a separately incorporated advocacy affiliate of the Alzheimer's Association. AIM works to develop and advance policies to overcome Alzheimer's disease through increased investment in research, enhanced care and improved support. For more information, visit

Recent Posts
CMS Draft Coverage Decision Expert Panel Discussion
January 28, 2022
National Voter Poll Finds Americans on Both Sides of the Aisle Support Medicare Covering Alzheimer’s Treatments
December 8, 2021
Protecting Our Most Vulnerable
May 19, 2020
Alzheimer's: A 2018 Election Issue
November 5, 2018
Exciting Alzheimer’s Research Presented in Chicago
July 26, 2018
Bold Action on Alzheimer's
June 12, 2018
Taking the Case to Congress
April 26, 2018
FDA Issues Draft Guidance on Alzheimer's drug development
February 16, 2018
AIM, Alzheimer’s Association Appeal for Increased Federal Research Funding at NIH Answered
May 5, 2017
Continuing to Drive the Pace of Alzheimer's Research
March 14, 2017
Ronald Reagan Fought Alzheimer's - Congress Can Honor His Legacy by Doing the Same
February 6, 2017
An Open Letter to HHS Secretary Nominee Tom Price
January 13, 2017
Welcome to Washington Mr. Trump and the 115th Congress
January 6, 2017
New Year, New Look, Same Commitment
December 29, 2016
Support for the 21st Century Cures Act
November 30, 2016
Alzheimer's Research: Where We've Failed and What's to Come
November 29, 2016
Looking Ahead to the Trump Administration and the 115th Congress
November 16, 2016
Campaign 2016 - The Year Alzheimer's Became a Campaign Trail Priority
November 8, 2016
AIM Supports Congressional Champions in Re-Election Bids
October 29, 2016
Honoring an Alzheimer's Champion
October 13, 2016
The Research Speaks, but Will Congress Listen in its Fight Against Alzheimer's Disease
August 15, 2016
Live from Philly
July 24, 2016
Live from Cleveland
July 18, 2016
Alzheimer's Fight Offers Rare Opportunity for Bipartisanship
July 7, 2016
Without Action, Alzheimer's Will Overwhelm Federal Budget by 2050 (Part III)
June 30, 2016
Without Action, Alzheimer's Will Overwhelm Federal Budget by 2050 (Part II)
June 23, 2016
Without Action, Alzheimer's Will Overwhelm Federal Budget by 2050 (Part I)
June 16, 2016